

## Correction: Allogeneic hematopoietic stem cell transplantation for relapsed acute myeloid leukemia in ETO positive with reduced-intensity conditioning

**Zhi Guo<sup>1,2</sup>, Xiao-dong Liu<sup>2</sup> and Hui-ren Chen<sup>2</sup>**

<sup>1</sup> Department of Medical Oncology, National Cancer Center/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China

<sup>2</sup> Department of Hematology, PLA Army General Hospital, Beijing, 100700, China

**Correspondence to:** Zhi Guo, **email:** guozhi77@126.com

**Published:** March 15, 2019

**Copyright:** Guo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**This article has been corrected:** The correct author information, author affiliation and Corresponding author details are given below:

**Zhi Guo<sup>1,2</sup>, Xiao-dong Liu<sup>2</sup> and Hui-ren Chen<sup>2</sup>**

<sup>1</sup> Department of Medical Oncology, National Cancer Center/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China

<sup>2</sup> Department of Hematology, PLA Army General Hospital, Beijing, 100700, China

**Correspondence to:** Zhi Guo, **email:** guozhi77@126.com

Original article: Oncotarget. 2018; 9:524-538. <https://doi.org/10.18632/oncotarget.22612>